Early Detection Research Network

Li, Christopher

Contact Information

Email: mailto:cili@fredhutch.org
Fax:
EDRN Principal Investigator
1736
None given

To update contact information, please visit the Data Management and Coordinating Center.

Open Protocols

Protocol Name Biomarkers Datasets
Benign Breast Disease Team Project 0 0
Biomarkers to Distinguish Aggressive Cancers from Non-aggressive or Non-progressing Cancer 0 0
Breast Reference Set Application: Chris Li-FHCRC (2015) 0 0
DCIS Team Project 0 0
EDRN Breast and Ovary Cancer CVC, Study 3: Phase 3 Validation of screening decision rules in preclinical UKCTOCS serial samples 0 0
EDRN Breast and Ovary Cancer CVC, Study 4: Phase 3 Validation of Ovarian Cancer Serum Markers in Preclinical WHI Samples 0 0
EDRN Breast and Ovary Cancer CVC, Study 2: Phase 3 retrospective validation of ovarian cancer early detection markers in serial preclinical samples from the PLCO trial 0 0
EDRN Breast and Ovary Cancer CVC, Study 1: Preliminary validation of breast cancer early detection biomarker candidates from our WHI discovery project 0 0
Identification of biomarkers for ER+ breast cancer 0 0
Study 5: Phase 2 and 3 Validations of Putative Breast Cancer Early Detection Candidates 0 0
Validation of Early Detection Ovarian Cancer Biomarkers (Team Project) 148 0

Closed Protocols

Protocol Name Biomarkers Datasets
Breast Reference Set Application: Chris Li-FHCRC (2014) 0 0
Triple Negative Breast Cancer Team Project 77 0

Publications

Publication Name PubMed ID Journal
Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study. 26319120 Breast Cancer Res. Treat.
Dermcidin expression is associated with disease progression and survival among breast cancer patients. 24562771 Breast Cancer Res. Treat.
Designing early detection programs for ovarian cancer. 22180403 Ann. Oncol.
Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study. 22903690 Breast Cancer Res. Treat.
Discovery of novel plasma proteins as biomarkers for the development of incisional hernias after midline incision in patients with colorectal cancer: The ColoCare study. 27745870 Surgery
Early-Phase Studies of Biomarkers: What Target Sensitivity and Specificity Values Might Confer Clinical Utility? 27001493 Clin. Chem.
Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. 22155417 Gynecol. Oncol.
Identifying post-menopausal women at elevated risk for epithelial ovarian cancer. 26343159 Gynecol. Oncol.
Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening. 22750949 Cancer Prev Res (Phila)
Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer. 22962406 Cancer Epidemiol. Biomarkers Prev.
JAK2 expression is associated with tumor-infiltrating lymphocytes and improved breast cancer outcomes: implications for evaluating JAK2 inhibitors. 24764577 Cancer Immunol Res
Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule. 23248253 J. Clin. Oncol.
Potential role of HE4 in multimodal screening for epithelial ovarian cancer. 21917606 J. Natl. Cancer Inst.
Protein and glycomic plasma markers for early detection of adenoma and colon cancer. 27821646 Gut
Proteomic Analysis, Immune Dysregulation, and Pathway Interconnections with Obesity. 27769113 J. Proteome Res.

To update protocols, publications, biomarkers, or science data, please contact the Informatics Center.